Foscarnet BOS Solution for Infusion
Foscarnet
24 mg/ml
Gland Pharma Limited
| Pack size | 1 Bag (250 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 821.30 AED |
Indications
Foscarnet BOS Solution for Infusion is used for:
Cytomegaloviral retinitis, in AIDS patients, Aciclovir-resistant mucocutaneous, herpes simplex virus infection
Adult Dose
Intravenous
Cytomegaloviral retinitis in AIDS patients
Adult: Induction: 60 mg/kg given via infusion over 1 hour, every 8 hours for 2-3 weeks. Maintenance: 60 mg/kg once daily, increase to 90-120 mg/kg once daily if tolerated. If progression occurs, re-treat with induction regimen.
Aciclovir-resistant mucocutaneous herpes simplex virus infection
Adult: In immunocompromised patients: 40 mg/kg via infusion over 1 hour, every 8 hours for 2-3 weeks or until lesions heal.
Child Dose
<18 years old: Safety and efficacy not established
Renal Dose
Administration
IV Preparation
Should be diluted in D5W or NS & transferred to PVC containers
For peripheral line administration, dilute to 12 mg/mL with D5W or NS
For central line administration, may administer undiluted
IV Administration
Use an infusion pump, not exceeding 1 mg/kg/min
Adult induction doses of 60 mg/kg are administered over a minimum 1 hr
Adult maintenance doses of 90-120 mg are infused over 2 hr
Contra Indications
Hypersensitivity
Precautions
Caution with renal impairment
Do not administer by rapid or bolus IV injection; use infusion pump
May be associated with changes in serum electrolytes changes including hypocalcemia, hypo- or hyperphosphatemia, hypomagnesemia, or hypokalemia
Serious acute hypersensitivity reactions (e.g., anaphylactic shock, urticaria, angioedema) reported; if such acute reactions occur, discontinue therapy; and institute appropriate medical therapy immediately
Cases of status epilepticus reported; several cases of seizures associated with death; electrolyte abnormalities may increase risk of seizures
Pregnancy-Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk, do not nurse
Interactions
May enhance nephrotoxic effect with aminoglycosides, amphotericin B, ciclosporin, aciclovir, methotrexate and tacrolimus. Increased risk of QT prolongation with antiarrhythmic agents (e.g. quinidine, amiodarone, sotalol).
Adverse Effects
Side effects of Foscarnet :
>10%
Fever (65%)
Nausea (47%)
Anemia (33%)
Vomiting (33%)
Diarrhea (30%)
Abnormal renal function/decreased CrCl (27%)
Headache (26%)
Seizures (10%)
1-10%
Fatigue
Depression
Confusion
Anxiety
Dizziness
Hypoesthesia
Malaise
Rash
Electrolyte imbalance (especially potassium, calcium, magnesium, and phosphorus)
Leukopenia
Neutropenia
Mechanism of Action
Foscarnet sodium is a non-nucleoside pyrophoshate analogue which acts as a noncompetitive inihibitor of many viral RNA and DNA polymerases as well as HIV reverse transcriptase.
Note
Foscarnet BOS 24 mg/ml Solution for Infusion manufactured by Gland Pharma Limited. Its generic name is Foscarnet. Foscarnet BOS is availble in Saudi Arabia.
Farmaco SA drug index information on Foscarnet BOS Solution for Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.